肺炎球菌结合疫苗在成人中的应用——应对非菌血症性肺炎球菌肺炎的未满足医疗需求
肺炎球菌是社区获得性肺炎的常见病因,其中非菌血症性肺炎疾病负担最大。美国及全球已批准用于成人的肺炎球菌疫苗有23价多糖疫苗(PPV23)和13价结合疫苗(PCV13);PPV23诱导的免疫应答短暂且无回忆应答,PCV13可产生免疫记忆和回忆应答。尽管PPV23已使用30年,其对非菌血症性肺炎的效力仍存争议;而PCV13对疫苗型肺炎球菌社区获得性肺炎(包括菌血症性和非菌血症性)的效力已在大型随机对照试验中得到证实。PCV13通过美国食品药品监督管理局加速通道获批,现已在全球越来越多地被推荐使用。本文总结了PPV23和PCV13在成人中的使用历史与现状,以及PCV13接种如何满足未满足的医疗需求。
要点
- 肺炎球菌是社区获得性肺炎的常见病因,非菌血症性肺炎疾病负担最大。
- PPV23诱导的免疫应答短暂且无回忆应答;PCV13可产生免疫记忆和回忆应答。
- PCV13对疫苗型肺炎球菌社区获得性肺炎(含菌血症性和非菌血症性)的效力已在大型随机对照试验中证实。
核心结论
- PCV13对疫苗型肺炎球菌社区获得性肺炎(包括菌血症性和非菌血症性)的效力已在大型随机对照试验中得到证实,其使用现已在全球越来越多地被推荐。
研究设计与样本
- 本文为综述,总结PPV23和PCV13在成人中的使用历史与现状。
主要发现
- 肺炎球菌是社区获得性肺炎的常见病因,非菌血症性肺炎疾病负担最大。
- PPV23中的荚膜多糖主要通过T细胞非依赖性机制诱导抗体,免疫应答短暂且缺乏回忆应答能力。
- PCV13将细菌多糖共价结合至免疫原性载体蛋白,形成记忆B淋巴细胞,从而产生长效免疫记忆和回忆应答。
- 尽管PPV23已使用30年,其对非菌血症性肺炎的效力仍被广泛讨论和研究。
- PCV13对疫苗型肺炎球菌社区获得性肺炎(包括菌血症性和非菌血症性)的效力已在大型随机对照试验中证实。
临床怎么用
- PCV13通过美国食品药品监督管理局加速通道获批,该通道允许对现有治疗提供有意义的益处的产品更早获批,本例中即保护成人免于非菌血症性肺炎球菌肺炎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Streptococcus pneumoniae is a frequent cause of community acquired pneumonia (CAP), with the largest burden of disease attributed to non-bacteremic pneumonia. Due to the high persistent burden of disease, pneumococcal pneumonia, particularly non-bacteremic pneumococcal pneumonia, continues to be a major public health concern. There are currently two pneumococcal vaccines approved for use in adults in the United States (US) and other countries worldwide: a 23-valent pneumococcal simple polysaccharide vaccine (PPV23), and a 13-valent pneumococcal conjugate vaccine (PCV13). The capsular polysaccharides included in PPV23 induce antibodies primarily by a T-cell independent mechanism, thus the immune response is short lived and lacks the ability to elicit an anamnestic response. PCV13, on the other hand, has the bacterial polysaccharides covalently conjugated to an immunogenic carrier protein resulting in the formation of memory B lymphocytes, thus proving long-acting immunologic memory and an anamnestic response. Despite 30years of use, the question of PPV23 vaccine efficacy, particularly with respect to efficacy for non-bacteremic pneumonia, has been extensively debated and investigated; whereas PCV13 efficacy against vaccine-type pneumococcal CAP, both bacteremic and non-bacteremic, was confirmed in a large randomized controlled trial in older adults. PCV13 was approved under the US Food and Drug Administration's accelerated pathway, which allows for earlier approval of products that provide meaningful benefit over existing treatments - in this case, protection of adults from non-bacteremic pneumococcal pneumonia. Its use is now increasingly recommended globally. This article summarizes the history and use of PPV23 and PCV13 in adults and how vaccination of adults with PCV13 addresses an unmet medical need.
引用
- Sings HL. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017. PMID: 28602602. doi:10.1016/j.vaccine.2017.05.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。